Next stop Australia for GSK drug?

Posted 29 May 2025 AM

GSK has landed a marketing authorisation recommendation for its long-awaited antibody-drug conjugate (ADC) Blenrep in Europe, giving local registration prospects a boost.

In 2020, the FDA signed off on Blenrep as a monotherapy for multiple myeloma (MM) patients who had tried at least four other treatments, but two years later, the ADC was pulled from the market after coming up short in a confirmatory trial.

To see the whole article, please login